Quarterly results

Latest results

2018 Second Quarter and R&D update

Released 25 July 2018

We announced our second quarter 2018 results on Wednesday 25 July and hosted an investor event where Emma Walmsley, CEO, and Simon Dingemans, CFO, spoke about our performance and financial outlook, and Hal Barron, Chief Scientific Officer and President, R&D, presented our R&D update.

Watch Emma Walmsley, CEO, give a summary of our performance at Q2 2018.

Find out more about our R&D update.

Highlights

Q2 2018 results infographic

2013 First Quarter - released 24 April 2013
Released 24 April 2013
Simon Dingemans, CFO, discusses our first quarter results 2013.
- Listen to the webcast
- View the press release
Related downloads
2012 Fourth Quarter - released 06 February 2013
Released 06 February 2013
Simon Dingemans, CFO, and Sir Andrew Witty, CEO, discuss our fourth quarter results 2012.
- Listen to the webcast
- View the press release
Key highlights
- Core EPS of 112.7p and returns of £6.3bn to shareholders
- 2012 dividend of 74p (+6%)
- Group sales -1%; flat excluding disposals of OTC brands
- Successful R&D delivery: six new drugs filed since start of 2012
Related downloads
2012 Third Quarter - released 31 October 2012
Released 31 October 2012
Simon Dingemans, CFO, discusses our Q3 results 2012.
- Listen to the webcast
Key highlights
- Core EPS of 26.5p
- Dividend of 18p (+ 6%)
- Further successful R&D delivery: phase III programmes completed for 6 novel medicines in 2012
- Continued strong cash generation and returns to shareholders
Related downloads
2012 Second Quarter - released 25 July 2012
Released 25 July 2012
Watch Sir Andrew Witty, CEO, discuss our second quarter results 2012.
- CEO Sir Andrew Witty discusses second quarter results
- View the press release
Key highlights
- Core EPS of 26.4p
- Dividend of 17p (up 6%)
- Significant late-stage pipeline delivery
Related downloads

1
2
3
4
5
6
7
8
9

Back to top

Other key information